Abstract
Receptor abnormalities have been documented in myocardial samples obtained by endomyocardial biopsy or during surgery or autopsy. Positron Emission Tomography now allows to obtain noninvasively quantitative determination of regional receptor density and affinity in humans as well as innervation integrity and function. These measurements are based upon the synthesis of a radioligand, usually either a selective receptor antagonist or a false neurotransmitter labeled with a positron-emitting radioisotope. Mathematical compartmental models are fitted to activity vs.time curves obtained during saturation or displacement experiments in order to calculate the rate constants and the receptor density in meaningful regions-of-interest selected in the myocardium. Several receptor classes, adrenergic, muscarinic-cholinergic, peripheral-type benzodiazepine, have thus been characterized in humans. PET can help understand changes in cardiac innervation.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Allman, K., Wieland, D., Muzik, O., et al.: Carbon-11 Hydroxyephedrine with Positron Emission Tomography for Serial Assessment of Cardiac Adrenergic Neuronal Function after Acute Myocardial Infarction in Human. J. Am. Coll. Cardiol. 22:368–75, 1993.
Beau, S.L., and Saffitz, J.E.: Transmural heterogeneity of norepinephrine in failing human hearts. J. Am. Coll. Cardiol. 23:579–595, 1994.
Beau, S.L., Tolley, T.K. and Saffitz, J.E.: Heterogeneous transmural distribution of beta-adrenergic receptor subtypes in failing human hearts. Circulation 88:2501–2509, 1993.
Berger, G., Mazière, M., Prenant, C, Sastre, J., Syrota, A., and Comar, D.: Synthesis of C-11-propranolol. J.Radioanal. Chem. 74:301–306, 1982.
Berger, G., Prenant, C, Sastre, J., Syrota, A., and Comar, D.: Synthesis of a beta-blocker for heart visualization: [11C]practolol. Int. J. Appl. Radiat. Isot. 34:1556–1557, 1983.
Berridge, M., Comar, D., Crouzel, C, and Baron, J.C.: C-11-labelled ketanserin, a selective serotonin S2 antagonist. J. Label. Compds. Radiopharm. 20:73–78, 1983.
Böhm, M., La Rosée, K., Schwinger, R.H. and Erdmann, E.: Evidence for reduction of norepinephrine uptake sites in the failing human heart. J. Am. Coll. Cardiol. 25:146–153, 1995.
Boullais, C, Crouzel, C, and Syrota, A.: Synthesis of 4-(3-t-Butylamino-2-hydroxypropoxy)-benzimidazol-2(11C)-one (CGP 12177). J.Label. Compds. Radiopharm. 23:565–567, 1986.
Bristow, M.R., Ginsburg, R., Minobe, W., et al.: Decreased catecholamine sentivity and beta-adrenergic receptor density in failing human heart. N. Engl. J. Med. 307:205-211, 1982.
Bristow, M.R., Kantrowitz, N.E.,Ginsburg, R., Fowler, M.R.: ß-Adrenergic function in heart muscle disease and in heart failure. J. Mol. Cell. Cardiol. 17:41-52, 1985.
Bristow, M.R., Ginsburg, R., Umans, V., et al.: Beta-1 and beta-2 adrenergic receptor subpopulations in nonfailing and failing human ventricular myocardium: coupling of both receptor subtypes to muscle contraction and selective beta-1 receptor down-regulation in heart failure. Circ. Res. 59:297–309, 1986.
Bristow, M.R., Hershberger, R.E., Port, J.D., and Rasmussen, R.: β1 and β2 adrenergic receptor mediated adenylate cyclase stimulation in nonfailing and failing human ventricular myocardium. Mol. Pharmacol. 35:295–303, 1989a.
Bristow, M.R., Port, J.D., and Gilbert, E.M.: The role of adrenergic receptor regulation in the treatment of heart failure. Cardiovasc. Drug. Ther. 3:971–978, 1989b.
Bristow, M.R., Anderson, A.L., Port, JD., et al.: Differences in beta-adrenergic receptor neuroeffector mechanisms in ischemic versus idiopathic dilated cardiomyopathy. Circulation 84:1024–1039, 1991.
Bristow, M.R., Minobe, W., Rasmussen, R., et al.: ß-Adrenergic neuroeffector abnormalities in the failing human heart are produced by local rather than systemic mechanisms. J. Clin. Invest. 89:803–815, 1992
Bristow, M.R., Minobe, W.A., Raynolds, M.V., et al.: Reduced beta-1 receptor mRNA abundance in the failing human heart. J. Clin. Invest. 92:2737–2745, 1993.
Brodde, O.E., Schuler, S., Kretsch, R., et al.: Regional distribution of β-adrenoceptors in the human heart: coexistence of functional β1 and β2-adrenoceptors in both atria and ventricles in severe congestive cardiomyopathy. J. Cardiovasc. Pharmacol. 8:1235–1242, 1986.
Brodde, O.E., Broede, A., Daul, A., Kunde, K. and Michel, M.C. Receptor Systems in the Non-Failing Human Heart. Basic Res. Cardiol. 87:1–14, 1992.
Brown, J.H., and Goldstein, D.: Analysis of cardiac muscarinic receptors recognized selectively by nonquatemary but not by quaternary ligands. J. Pharmaco. Exp. Ther. 238: 580–586, 1986.
Brush, J.E., Eisenhofer, G., Garty, M., et al.: Cardiac norepinephrine kinetics in hypertrophic cardiomyopathy. Circulation 79: 836–844, 1989.
Calkins, H., Lehmann, M., Allman, K., Wieland, D. and Schwaiger, M. Scintigraphic Pattern on Regional Cardiac Sympathetic Innervation in Patients with Familial long QT Syndrome using Positron Emission tomography. Circulation 87:1616–1621, 1993.
Camsonne, R., Crouzel, C, Comar, D., et al.: Synthesis of N-(11C)Methyl, N-(Methyl-1 Propyl), (Chloro-2 Phenyl)-1 Isoquinoleine carboxamide receptors. J. Label. Compds. Radiopharm. 21:985–991, 1984.
Chang, P.C., Szemeredi, K., Grossman, E., Kopin, I.J., and Goldstein, D.S.: Fate of tritiated 6-fluorodo-pamine in rats: a false neurotransmitter for positron emission tomographic imaging ol sympathetic innervation and function. J. Pharmacol. Exp. Ther. 255:809–17, 1990.
Changeux, J.P.: The acetylcholine receptor: an “allosteric” membrane protein. Harvey Lect. 75:85–254, 1981.
Charbonneau, P., Syrota, A., Boullais, C, and Crouzel, C: Serotonin receptors and lung phagocyte recruitment induced by cigarette smoking detected in vivo by positron emission tomography. J. Nucl. Med. 27:950, 1986.
Charbonneau, P., Syrota, A., Crouzel, C, Valois, J.M., Prenant, C, and Crouzel, M.: Peripheral-type benzodiazepine receptors in the living heart characterized by positron emission tomography. Circulation 73:476–483, 1986.
Chidsey, C.A., Braunwald, E., and Morrow, A.G.: Catecholamine excretion and cardiac stores of norepinephrine in congestive heart failure. Am. J. Med. 39:442–451, 1965.
Clerc, J., Mardon, K., Galu, J.M.,et al.: MBBG versus MIBG for imaging and targeting of the xenografted PC12-pheochromocytoma cell line with SIMS microscopy assessment of their intratumor biodistribution and uptake. J. Nucl. Med. 1995 (in press)
Cohn, J.N., Levine, B.T., Olivari, M.T., et al.: Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N. Engl. J. Med. 311:819–823, 1984.
Colucci, W.S., Denniss, A.R., Leatherman, G.F., et al. .: Intracoronary infusion of dobutamine to patients with and without severe congestive heart failure. J. Clin. Invest. 81:1103–1110, 1988.
Crouzel, C, Venet, M., Irié, T., Sanz, G., and Boullais, C: Labeling of a serotoninergic ligand with 18F: [18F]setoperone. J. Label. Compds. Radiopharm. 25:403–414, 1988a.
Crouzel, C, Venet, M., Sanz, G., and Denis, A.: Labelling of a new serotoninergic ligand: [18F]ritanserine. J. Label. Compds. Radiopharm. 25:827–832, 1988b.
Dasilva, J.N., Kilbourn, M.R. and Mangner, T.J. Synthesis of [C-11]Tetrabenazine, a Vesicular Monoamine Uptake Inhibitor, for PET Imaging Studies. Appl.RadiatIsotopes. 44:673–676, 1993.
De Grado, T.R., Hutchins, G.D., Toorongian, S.A., Wieland, D.M. and Schwaiger M. Myocardial kinetics of Carbon-11-Meta Hydroxyephedrine: retention mechanisms and effects of norepinephrine. J. Nucl. Med. 34:1287–1293, 1993.
DeGrado, T.R., Mulholland, G.K., Wieland, D.M. and Schwaiger, M. Evaluation of (-)[f-18]fluoroethoxy benzovesamicol as a New Pet Tracer of Cholinergic Neurons of the Heart. Nucl.Med. Biol. 21:189–195, 1994.
Delforge, J., Syrota, A., and Mazoyer, B.: Experimental design optimization: theory and application to estimation of receptor model parameters using dynamic positron emission tomography. Phys. Med. Biol. 34:419–435, 1989.
Delforge, J., Syrota, A. and Mazoyer, B.M. Identifiability Analysis and Parameter Identification of an Invivo Ligand-Receptor Model from Pet Data. IEEE Trans.Biomed.Eng. 37:653–661, 1990a.
Delforge, J., Janier, M., Syrota, A., et al.: Noninvasive quantification of muscarinic receptors in vivo with positron emission tomography in the dog heart. Circulation 82:1494–1504, 1990b.
Delforge, J., Syrota, A., Lancon, J.P., et al.: Cardiac beta-adrenergic receptor density measured in vivo using PET, CGP 12177 and a new graphical method. J. Nucl. Med. 32:739–748, 1991.
Delforge, J., Leguludec, D., Syrota, A., et al.: Quantification of Myocardial Muscarinic Receptors with PET in Humans. J.Nucl.Med. 34:981–991, 1993.
Ding, Y., Fowler, J., Dewey, S., et al.: Comparaison of High Specific Activity (-) and (+)−6 [18F]Fluoronorepinephrine and 6-[18F]Fluorodopamine in baboons: heart uptake, metabolism and the effect of desipramine. J. Nucl. Med. 34:619–629, 1993.
Ehrin, E., Luthra, S.K., Crouzel, C, and Pike, V.W.: Preparation of carbon-11 labelled prazosin, a potent and selective alpha-1 adrenoceptor antagonist. J. Label. Compds. Radiopharm. 25:177–183, 1988.
Farde, L, Haldin, C, Nagren, K. et al.: Positron emission tomography shows high specific uptake of racemic carbon-11 labelled norepinephrine in the primate heart. Eur. J. Nucl. Med. 21:345–347, 1994.
Gibson, R.E., Eckelman, W.C., Vieras, F., and Reba, R.C: The distribution of the muscarinic acetylcholine receptor antagonists, quinuclidinyl benzilate and quinuclidinyl benzilate methiodide (both triated) in rat, guinea pig and rabbit. J. Nucl. Med. 20:865–870, 1979.
Gitler, M.S., Delacruz, R., Zeeberg, B.R. and Reba, R.C. [H-3]QNB displays in vivo selectivity for the m2 subtype. Life Sci. 55:1493–1508, 1994.
Goldstein, D.S., Chang, P.C., Eisenhofe,r G., et al.: Positron Emission tomographic imaging of cardiac sympathetic innervation and function. Circulation 81:1606–1621, 1990.
Golf, S., Lfvstad, R., and Hansson, V.: beta-adrenoceptor density and relative number of beta-adrenoceptor subtypes in biopsies from human right atrial, left ventricular and right ventricular myocard. Cardiovasc. Res. 19:636–641, 1985.
Golf, S., Myrhe, E., Abdelnoor, M., Andersen, D and Hansson, V.: Hypertrophic cardiomyopathy characterized by beta-adrenoceptor density, relative amount of beta-adrenoceptor subtypes and adenylate cyclase activity. Cardiovasc. Res. 19:693–699, 1985.
Gossuin, A., Maloteaux, J.M., Trouet, and Laduron, P.: Differentiation between ligand trapping into intact cells and binding on muscarinic receptors. Biochim. Biophys. Acta. 804:100–106, 1984.
Hammadi, A., and Crouzel, C.: Asymetric synthesis of (2S) and (2R)-4-(butylamino-2-hydroxypropoxy-benzamidazol-2-C-11) one ((S) and (R) (C-11 CGP 12177 from optically active precursors. J. Lab. Compds. Radiopharm. 29: 681–690, 1991.
Hartvig, P., Lindner, K.J., Tedroff, J. and Langstrom, B. Positron emission tomography-illuminating in vivo drug disposition. Eur.J.Pharm.Sci. 2:44–46, 1994.
Heitz, A., Schwartz, J., and Velly, J.: Beta-adrenoceptors of the human myocardium: determination of β1 and β2 subtypes by radioligand binding. Br. J. Pharmacol. 80:711–717, 1983.
Hertel, C, Muller, P., Portenier, H., and Staehelin, M.: Determination of the desensitization of beta-adrenergic receptors by [3H]CGP-12 177. Biochem. J. 216:669–674, 1983.
Hoover, D.B., Baisden, R.H. and Ximoy, S.X. Localization of muscarinic receptor mRNAs in rat heart and intrinsic cardiac ganglia by in situ hybridization. Circ.Res. 75:813–820, 1994.
Hulme, E.C., Birdsall, N.J.M. and Buckley, N.J. Muscarinic receptor subtypes. Annu.Rev.Pharmacol.Toxicol. 30:633–673, 1990.
Karliner, J.S., Stevens, M., Grattan, M., Woloszyn, W., Honbo, N., and Hoffman, J.I.E.: Beta-adrenergic receptor properties of canine myocardium: effects of chronic myocardial infarction. J. Am. Coll. Cardiol. 8:349-356, 1986.
Kaumann, A.J.: Some aspects of heart beat adrenoreceptor function. Cardiovasc. Drugs Ther. 5:549–560, 1991.
Kelly, R.B. Storage and Release of Neurotransmitters. Neuron 10 suppl:43–53, 1993.
Kilboum, M.R., Jung, Y.W., Haka, M.S., Gildersleeve, D.L, Kuhl, D.E., and Wieland, D.M.: Mouse brain distribution of a carbon-11 labeled vesamicol derivative: presynaptic marker of cholinergic neurons. Life. Sci. 47:1955–63, 1990.
Kiuchi, K., Sato, N., Shannon, R.P., Vatner, D.E., Morgan, K. and Vatner, S.F. Depressed beta-Adrenergic Receptor-Mediated and Endothelium-Mediated Vasodilation in Conscious Dogs with Heart Failure. Circ.Res. 73:1013–1023, 1993.
Lefroy, D.M. de Silva, R., Choudhury, L. et al.: Diffuse reduction in myocardial beta-adrenoceptors in hypertrophic cardiomyopathy: a study with positron emission tomography. J. Am. Coll. Cardiol. 22: 1653–1660, 1993.
Leguludec, D., Delforge, J., Syrota, A., et al.: In vivo quantification of myocardial muscarinic receptors in heart transplant patients. Circulation 90:172–178, 1994.
Loc’H, C., Mardon, K., Valette, H.,et al.: Preparation and pharmacological characterization of 76-meta-bromobenzylguanidine (76-MBBG). Nucl. Med. Biol. 21:49–55, 1994.
Maisel, A.S., Motulsky, H.J., and Insel, P.A.: Externalisation of beta-adrenergic receptors promoted by myocardial ischemia.Science 230:183–186, 1985.
Maron, B.J., Bonow, R.O., Cannon, R.O., Leon, M.B., and Epstein, S.E.: Hypertrophic cardiomyopathy. N. Engl. J. Med. 316 (13):780–789, 1987.
Mazière, M., Comar, D., Godot, J.M., Collard, P., Cepeda, P., and Naquet, R.: In vivo characterization of myocardium muscarinic receptors by positron emission tomography. Life Sci. 29:2391–2397, 1981.
Melon, P.G., Nguyen, N., Degrado, T.R., Mangner, T.J., Wieland, D.M., Schwaiger, M.: Imaging of cardiac neuronal function after cocaine exposure using C-11-hydroxyephedrine and positron emission tomography. J. Am. Coll. Cardiol. 23:1693–1699, 1994.
Merlet, P., Dubois Randé, J.L., Adnot, S., et al.: Myocardial beta adrenergic desensitization and neuronal norepinephrine uptake function in idiopathic cardiomyopathy. J. Cardiovasc. Pharmacol. 19:10–16, 1992a.
Merlet, P., Valette, H., Dubois Randé, J.L, et al.: Prognostic value of cardiac MIBG imaging in patients with congestive heart failure. J. Nucl. Med. 33:471–477, 1992b.
Merlet, P., Delforge, J., Syrota, A., et al.: Positron Emission Tomography with 11C CGP-12177 to assess β-Adrenergic Receptor Concentration In Idiopathic Dilated Cardiomyopathy. Circulation 87:1169–1178, 1993.
Minardo, J.D., Tulli, M.M., Mock, B.H., et al.: Scintigraphic and electrophysiologic evidence of canine myocardial sympathetic denervation and reinnervation produced by myocardial infarction or phenol application. Circulation 78:1008–1019, 1988.
Mislankar, S.G., Gildersleeve, D.L, Wieland, D.M., Massin, G.C., Mulholland, G.K., and Toorongian, S.A.: 6-[18F]fluorometaraminol: a radiotracer for in vivo mapping of adrenergic nerves of the heart. J.Med. Chem. 31:362–366, 1988.
Moran, A., Velasco, C, Martin, M. and San Roman, L Pharmacological characterization of 5-HT receptors in parasympathetic innervation of rat heart. Eur. J.Pharmacol. 252:161–166, 1994.
Motulsky, H.J. Pet Receptors — Counting Receptors Using Positron Emission Tomography. Circulation 82:1536–1538, 1990.
Mukherjee, A., Wong, T.M., Buja, L.M., Lefkowitz, R.J., and Willerson, J.T.: Beta adrenergic and muscarinic cholinergic receptors in canine myocardium: Effects of ischemia. J. Clin. Invest. 64: 1423–1428, 1979.
Mukherjee, A., Bush, L.R., McCoy, K.E., et al.: Relationship between beta-adrenergic receptor numbers and physiological responses during experimental canine myocardial ischemia. Circ. Res. 50:735–741, 1982.
Mukherjee, A., Haghani, Z., Brady, J., et al.: Differences in myocardial alpha- and beta-adrenergic receptor numbers in different species. Am. J. Physiol. (Heart Circ. Physiol. 14) 245:H957–H961, 1983.
Mulholland, G.K., Schwaiger, M., Sherman, P.S., Jewett, D.M., and Otto, C.A.: New positron labeled quatemized muscarinic ligand as potential PET imaging agent. Circulation 78:11–598, 1988.
Mulholland, G.K., Jung, Y.W., Wieland, D.M., Kilboum, M.R. and Kuhl, D.E. Synthesis of [F-18]Fluoroethoxy-Benzovesamicol, a Radiotracer for Cholinergic Neurons. J.Label.Compound.Radiopharm. 33:583–591, 1993.
Murphee, S.S.,and Saffitz, J.E.: Distribution of adrenergic receptors in failing human heart: Implications for mechanisms of down regulation. Circulation 79:1214–1225, 1989.
Nakajima, K., Bunko, H., Taki, J., Shimizu, M., Muramori, A., and Hisada, K.: Quantitative analysis of 123l-metaiodobenzylguanidine (MIBG) uptake in hypertrophic cardiomyopathy. Am. Heart. J. 119:1329–1337, 1990.
Nanoff, C, Freissmuth, M., and Schütz, W.: The role of a low beta-1 adrenoceptor selectivity of [3H]CGP-12177 for resolving subtype-selectivity of competitive ligands. Naunyn-Schmiedeberg’s Arch Pharmacol. 336:519–525, 1987.
Pascal, O., Syrota, A., Berger, G., et al.: Lung uptake of C-11-lmipramine and C-11-Propranolol in patients with sarcoïdosis evaluated by positron emission tomography, in J. Marsac, J. Chretien (eds): Sarcoïdosis and other granulomatous disorders, Pergamon Press, Paris,, 404–408, 1981.
Petch, M.C., and Nayler, W.G.: Uptake of catecholamines by human cardiac muscle in vitro. Br. Heart. J. 41:336–339, 1979.
Prenant, C, Sastre, J., Crouzel, C, and Syrota, A.: Synthesis of C-11-Pindolol. J. Label. Compds.Radiopharm. 24:227–232, 1987.
Rogers, G.A., Stoneelander, S., Ingvar, M., Eriksson, L, Parsons, S.M. and Widen, L. F-18-Labelled Vesamicol Derivatives - Syntheses and Preliminary in Vivo Small Animal Positron Emission Tomography Evaluation. Nucl.Med. Biol. 21:219–230, 1994.
Rose, C, Burgess, J.H., and Cousineau, D.: Tracer norepinephrine kinetics in coronary circulation of patients with heart failure secondary to chronic pressure and volume overload. J. Clin. Invest. 76:740–747, 1985.
Rosenspire, K.C., Haka, M.S., Van Dort, M.E., et at.: Synthesis and preliminary evaluation of carbon-11-meta-hydroxyephedrine: a false transmitter agent for heart neuronal imaging. J. Nucl. Med. 31:1328–34, 1990.
Sandoval, A.B., Gilbert, E.M., Rose, C.P., and Bristow, M.B.: Cardiac norepinephrine uptake and release is decreased in dilated cardiomyopathy (abstr). Circulation 80 (suppl. II):393, 1989.
Schwaiger, M., Guibourg, H., Rosenpire, K., et al.: Effect of Regional Myocardial Ischemia on sympathetic nervous systems as assessed by Fluorine-18-Metaraminol. J. Nucl. Med. 31:1352–1357, 1990a.
Schwaiger, M., Kalff, V., Rosenpire, K., et al.: Noninvasive evaluation of sympathetic nervous system in human heart by positron emission tomography. Circulation 82:457–464, 1990b.
Schwaiger, M., Hutchins, G.D., Kalff, V., et al.: Evidence for regional catecholamine uptake and storage sites in the transplanted human heart by positron emission tomography. J. Clin. Invest. 87: 1681–90, 1991.
Seto, M., Syrota, A., Crouzel, C, et al.: Beta adrenergic receptors in the dog heart characterized by C-11-CGP 12 177 and PET. J. Nucl. Med. 27:949, 1986.
Simon, G., Filep, J. and Zelles, T. Alpha-Adrenergic Drugs Inhibit <H-3>-QNB Binding to Muscarinic Receptors of Rat Heart, Brain and Parotid Gland Membranes. Life Sci. 47:2021–2025, 1990.
Spann, J.F., Chidsey, C.A., Pool, P.E., and Braunwald, E.: Mechanism of norepinephrine depletion in experimental heart failure produced by aortic constriction in the guinea pig. Circ. Res. 17:312–321, 1965.
Staehelin, M., Simons, P., and Jaeggik Wigger, N.: CGP-12 177. A hydrophilic beta-adrenergic receptor radioligand reveals high affinity binding of agonists to intact cells. J. Biol. Chem. 258:3496–3502, 1983.
Stiles, G.L., Caron, M.G., and Lefkowitz, R.J.: ß-Adrenergic receptors: biochemical mechanisms of physiological regulation. Physiol. Rev. 64:661–743, 1984.
Syrota, A., Paillotin, G., Davy, J.M., and Aumont, M.C.: Kinetics of in vivo binding of antagonist to muscarinic cholinergic receptor in the human heart studied by Positron Emission Tomography. Life Sci. 35:937–945, 1984.
Syrota, A., Comar, D., Paillotin, G., et al.: Muscarinic cholinergic receptor in the human heart evidenced under physiological conditions by positron emission tomography. Proc. Natl. Acad. Sci. USA 82:584–588, 1985.
Syrota, A.: Positron Emission Tomography: Evaluation of cardiac receptors. In: Marcus ML, Skorton DJ, Schelbert HR, Wolf GL, eds, Braunwald E (consulting ed); Cardiac Imaging — Principles and practice: a companion of Braunwald’s heart disease. Eds, E. Braunwald, consulting ed., W.B. Saunders Comp., pp 1256–1270, 1991.
Takahashi, N., Barber, M.J., and Zipes, D.P.: Efferent vagal innervation of canine ventricle. Ann. J. Physiol. (Heart. Circ. Physiol. 17) 248:H89–H97, 1985.
Thomas, J.A., Marks, B.H.. Plasma norepinephrine in congestive heart failure. Am. J. Cardiol. 41:233–243, 1978.
Ungerer, M., Bohm, M., Elce, J.S., Erdmann, E., Lohse, M.J.: Altered expression of beta-adrenergic receptor kinase and beta-1 adrenergic receptors in the failing human heart. Circulation 87:454–463, 1993.
Valette, H, Loc’h, C, Mardon, K, et al.:. 76Br-Metabromobenzylguanidine: a PET radiotracer for mapping of sympathetic nerves of the heart. J. Nucl. Med. 34, 10: 1739–1744, 1993.
Van Dort, M.E., Gildersleeve, D.L, and Wieland, D.M.: Synthesis of 3H-labeled sympathomimetic amines for neuronal mapping. J. Label. Compounds. Radiopharm. 28:832–40, 1990.
Van Zuiten, P.A. Adrenergic and muscarinic receptors: classification, pathophysiological relevance and drug target. J.Hypertension 9:S18–S27, 1991.
Vatner, D.E., Lavallee, M., Amano, J., Finizola, A., Homcy, C.J., and Vatner, S.F.: Mechanisms of supersensitivity to sympathetic amines in the chronically denervated heart of the conscious dog. Circ. Res. 57:55–64, 1985a.
Vatner, D.E, Vatner, S.F., Fujii, A.M., and Homcy, C.J.: Loss of high affinity cardiac beta adrenergic receptors in dogs with heart failure. J. Clin. Invest. 76: 2259–2263, 1985b.
Vatner, D.E., Knight, D.R., Shen, Y.T., Thomas, J.X. Jr, Homcy, C.J., and Vatner, S.F.: One hour of myocardial ischemia in conscious dogs increases beta-adrenergic receptors, but decreases adenylate cyclase activity. J. Mol. Cell. Cardiol. 20:75-82, 1988a.
Vatner, D.E., Lee, D.L., Schwarz, K.R., et al.: Impaired cardiac muscarinic receptor function in dogs with heart failure. J. Clin. Invest. 81:1836–1842, 1988b.
Wieland, D.M., Brown, L.E., Les Roger, W., et al.: Myocardial imaging with a radioiodinated norepinephrine storage analog. J. Nucl. Med. 22:22–31, 1981.
Wieland, D.M., Hutchins, G.D., Rosenspire, K.C., et al.: (C11)Hydroxyephedrine: a high specific activity alternative to 6-(F18)fluorometaraminol for heart neuronal imaging. J. Nucl. Med. 30, 5:767, 1989.
Wieland, D.M., Rosenpire, K.C., Hutchkins, G.D., et al.: Neuronal mapping of the heart with 6-18F fluorometaraminol. J. Med. Chem. 33:956–964, 1990.
Wieland, D.M.: Heart neuronal imaging with C-11- and fluorine-18-labeled tracers. In: «What’s news in cardiac imaging?», E.E. van der Wall, H. Sochor, H. Righetti and M.G. Niemeyereds, Kluwer Academic Publisher, 413–426, 1992.
Wilkinson, M., Horackova, M. and Giles, A. Reduction of Ventricular M(2) Muscarinic Receptors in Cardiomyopathic Hamster (Chf 147) at the Necrotic Stage of the Myopathy. Pflugers Arch-Eur. J.Physiol. 426:516–523, 1994.
Woods, P.B., Robinson, M.L: An investigation of the comparative liposolubilities of β-adrenoceptor blocking agents. J. Pharm. Pharmacol. 33:172–173, 1981.
Yang, CM., Yeh, H.M., Sung, T.C., Chen, F.F. and Wang, Y.Y. Characterization of Muscarinic Receptor Subtypes in Canine Left Ventricular Membranes. J.Recept.Res. 12:427–449, 1992
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1995 Springer Science+Business Media Dordrecht
About this chapter
Cite this chapter
Syrota, A., Merlet, P. (1995). Myocardial Receptors and Their Interaction with Cardiovascular Drugs. In: Comar, D. (eds) PET for Drug Development and Evaluation. Developments in Nuclear Medicine, vol 26. Springer, Dordrecht. https://doi.org/10.1007/978-94-011-0429-6_21
Download citation
DOI: https://doi.org/10.1007/978-94-011-0429-6_21
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-010-4191-1
Online ISBN: 978-94-011-0429-6
eBook Packages: Springer Book Archive